Immune Resetting: B-Cell Mediated and Beyond on March 24-26, 2026 in Boston, United States

The era of blanket immunosuppression is ending. A new chapter in autoimmune therapy is unfolding, one where precision replaces broad suppression, and immune resetting takes centre stage. B-cell depletion therapies have paved the way, but the question remains: what's next?

Innovations such as cell therapy, T-cell engagers, bispecifics, and next-generation monoclonal antibodies are no longer distant possibilities, they're here, poised to redefine treatment paradigms. What was once blue-sky thinking is now becoming a reality, fueled by major investments and strategic acquisitions like Kite Pharma's move for Interius Biotherapeutics and AbbVie's acquisition of Capstan. Rising interest in targets such as BCMA for lupus nephritis signals a seismic shift toward curative potential.

Harnessing this energy, the inaugural Immune Resetting: B-Cell Mediated and Beyond Summit launches at this pivotal moment, uniting biopharma leaders, academic KOLs, and immunology innovators to accelerate progress. From discovery through clinical application, this is your opportunity to benchmark strategies, build partnerships, and take actionable insights back to your programs.

Join 50+ experts to explore how targeted interventions can recalibrate the immune system, delivering durable, transformative therapies for lupus, systemic sclerosis, rheumatoid arthritis, multiple sclerosis, and beyond. The future of autoimmune care is being written and you should be a part of it.

URLs:

Tickets: https://go.evvnt.com/3384779-2?pid=10008

Brochure: https://go.evvnt.com/3384779-3?pid=10008

Time: 8:00 AM - 5:00 PM

Prices:

Conference Only - Primary Pricing: USD 3099.00,

Conference + Workshop Day - Primary Pricing: USD 4397.00,

Conference Only - Discounted Pricing: USD 2699.00,

Conference + Workshop Day - Discounted Pricing: USD 3797.00,

Conference Only - Vendor Pricing: USD 3799.00,

Conference + Workshop Day - Vendor Pricing : USD 5297.00

Speakers: Brandon Law, Director – Clinical Development, Bristol Myers Squibb, Chloe Slichter, Director – Discovery Biology, Kite Pharma, Heather Raymon, Senior Vice President - Research and Early Development, Artiva Bio, Jason Stadanlick, Principal Scientist, Cabaletta Bio, Irina Shapiro, Vice President - Translational Research, Cullinan Therapeutics, Jeffrey Jones, Chief Medical Officer, Cullinan Therapeutics, Tom Wickham, Chief Scientific Officer, GentiBio, Steve Chapin, Senior Director – Preclinical Development, Hinge Bio, Jinyang Li, Principal Scientist, Innovent Biologics, Min Bao, Chief Medical Officer, Kali Therapeutics, Zhen Su, Chief Executive Officer and Member Board of Directors, Marengo Therapeutics, Tapan Maniar, Chief Medical Officer, Oblenio Bio, Jaideep Dudani, Chief Executive Officer, Ouro Medicines, Christian Furlan Freguia, Senior Vice President - Research, Rise Therapeutics, Jing Li, Founder and Chief Executive Officer, VelaVigo, Ricardo Grieshaber-Bouyer, Professor – Clinical Systems Immunology, Friedrich-Alexander- Universität Erlangen- Nürnberg, Mark Shlomchik, Distinguished Professor and UPMC Endowed Chair, University of Pittsburgh